Proactive Investors - Run By Investors For Investors

Cancer-focused Marker Therapeutics shares rise after update on clinical trial pipeline

The Houston, Texas-based immuno-oncology group gave an update on five clinical trials
Cancer-focused Marker Therapeutics shares rise after update on clinical trial pipeline
Cancer treatment-focused Marker Therapeutics saw shares gain on Friday

Marker Therapeutics Inc (NASDAQ:MRKR) saw its shares advance over 9% on the Nasdaq Friday after it updated investors on its clinical pipeline.

The Houston, Texas-based immuno-oncology group gave an update on five clinical trials using its targeted T-cell (MultiTAA) therapies and TPIV200, the group's peptide cancer vaccine product candidate.

In the latter (TPIV200) the group said enrolment of patients had been completed in a Phase 2 trial evaluating the drug as a therapy in patients of ovarian cancer in their first remission after surgery and platinum-based chemotherapy.

Interim data should be available by the year-end, the firm told investors.

In the triple-negative breast cancer trial, initial data from a dose-finding study of TPIV200 as maintenance therapy following first-line treatment showed a 96% immune response rate.

Elsewhere, in the lymphoma trial, 15 heavily pre-treated patients have been treated in a phase 1/2 study, the company said.

No relapses and no cases of cytokine release syndrome have been observed, while four of the six complete responders have remained in remission for three to 42 months post-infusion.

In acute lymphoblastic leukaemia, preliminary Phase 1 data showed a complete response rate of 88% over one to 22 months, the company revealed.

In the multiple myeloma trial, interim data from a Phase 1/2 trial showed an initial 100% disease control rate, including one complete responder and two partial responders, but three patients progressed after three to seven months.

Shares in New York added 9% to $6.40.

View full MRKR profile View Profile

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use